The start of dosing in PISCES III, the Phase IIb trial of ReNeuron’s CTX stem cell therapy for stroke disability, is in line with expectations and guidance. We look forward to top-line data in early 2020 with anticipation, and reiterate our positive stance.
24 Jan 2019
First patient treated in ‘PISCES III’ stroke trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First patient treated in ‘PISCES III’ stroke trial
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
24 Jan 2019 -
Author:
Dr Jens Lindqvist -
Pages:
3
The start of dosing in PISCES III, the Phase IIb trial of ReNeuron’s CTX stem cell therapy for stroke disability, is in line with expectations and guidance. We look forward to top-line data in early 2020 with anticipation, and reiterate our positive stance.